Megan Baldwin

Follow
Get notifications in MyBN when activity occurs.
Subscribe to BN Log In
Megan Baldwin
Megan Baldwin
Chief Executive, Managing Director since 2015 / Opthea

Dr Megan Baldwin has over 20 years of experience in angiogenesis and therapeutic strategies for cancer and ophthalmic indications.

Her experience included several years as a researcher in the group of leading angiogenesis expert Napoleone Ferrara, before moving to Genentech's commercial division and having responsibility for corporate competitive intelligence activities. She has developed commercial and scientific knowledge in the field of anti-angiogenic and oncology drug development.

Lists and Charts

Knowledge Bank : Person Roles

2012
Chief Executive, Managing Director since 2015
Opthea
Year started and most recent title

Total Shareholder Return as at 06/01/26

Rank Company 1 Yr 5 Yr
Opthea -25.93% -18.48%
View Full List
1658 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Share Transactions

25/11/25
Issued
Race Oncology
09/04/24
Other
Invex Therapeutics
01/03/24
$543.25k Sold
Opthea
Total value as at the date of the transaction
Powered by Morningstar ®

      Person Activity

      Megan Baldwin
      		NEW ROLE: Chief Executive, Managing Director since 2015, Opthea 03 Nov 2020

    Related Information

    Access to our data for Megan Baldwin is only available to paid subscribers with Data & Insights access.

    Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

    Megan Baldwin is linked to 1 organisation which is included in 1 list - Public Companies - non WA.

    To see the data you will need to Subscribe.

    X